Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of ONCOZ.ST is 12 and suggests 63% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr